Views: 1,851 | Downloads:
53
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Efficacy and Safety of Pueraria mirifica (Kwao Kruea Khao) for the Treatment of Vasomotor Symptoms in Perimenopausal Women : Phase II Study
Lamlertkittikul S 
,
V
,
V SURACHAI LAMLERTKITTIKUL, MD*,
VERAPOL CHAND EYING, MD**
Objectives: To evaluate the preliminary efficacy and safety of
Pueraria mirifica
in the treat-
ment of vasomotor symptoms.
Design: Open-label study.
Setting : Hat Yai Regional Hospital, Thailand.
Subjects : Pre and postmenopausal women with vasomotor symptoms, such as hot flushes
and night sweats. Other unpleasant symptoms, urogenital and psychological symptoms, were also
evaluated.
Material and Method : Patients were enrolled voluntarily and randomly received 50 mg or
IOOmg of
Pueraria miri.fica
in capsules, once daily for six months.
Results : Of the 48 enrolled patients, 11 cases were excluded for failing to complete the initial
work-up. Thirty-seven cases were evaluated. 20 of 37 (54.1%) randomly received a dose of 50 mg/day
of
Pueraria mirifica
(Group A), and 17 of 37 (45.9%) received 100 mg/day of
Pueraria mirifica
(Group
B). The mean of the modified Greene climacteric scale decreased from 35.6 to 26.6, 17.2 and 15.1 in
group A, while group B, declined from 32.6 to 21.0, 14.8 and 13.6 at 1-, 3-and 6-month respectively.
The mean serum estradiol, fluctuated from the baseline of 76.6 to 55.4, 56.7, 72.5, 69.2, 114.2 and
74.5 pg/ml at 1-, 2-, 3-, 4-, 5-and 6-month respectively. Whereas the mean serum follicle-stimulating
hormone (FSH)Iluteinizing hormone (LH) was stable in the range of; 27.1112.6, 28.3/12.9 and 22.5/
11.4 miU/ml at baseline, 3-and 6-month respectively.
Conclusions :
Pueraria mirifica,
containing phytoestrogens, relatively alleviated the climac-
teric symptoms in perimenopausal women. The transient negative profiles occurred in a small number
of subjects that included anemia, and liver profiles. While there was a slight decrease in lipoproteins
and an increase in hormonal profiles,
Pueraria mirifica
demonstrates great promise in the treatment
of climacteric symptoms among peri menopausal women. However, optimal doses should be clinically
assessed, to meet appropriate individual responses.
Key word :
Pueraria miri.fica,
Vasomotor Symptoms, Perimenopausal Women, Phytoestrogen
VERAPOL CHAND EYING, MD**
Objectives: To evaluate the preliminary efficacy and safety of
Pueraria mirifica
in the treat-
ment of vasomotor symptoms.
Design: Open-label study.
Setting : Hat Yai Regional Hospital, Thailand.
Subjects : Pre and postmenopausal women with vasomotor symptoms, such as hot flushes
and night sweats. Other unpleasant symptoms, urogenital and psychological symptoms, were also
evaluated.
Material and Method : Patients were enrolled voluntarily and randomly received 50 mg or
IOOmg of
Pueraria miri.fica
in capsules, once daily for six months.
Results : Of the 48 enrolled patients, 11 cases were excluded for failing to complete the initial
work-up. Thirty-seven cases were evaluated. 20 of 37 (54.1%) randomly received a dose of 50 mg/day
of
Pueraria mirifica
(Group A), and 17 of 37 (45.9%) received 100 mg/day of
Pueraria mirifica
(Group
B). The mean of the modified Greene climacteric scale decreased from 35.6 to 26.6, 17.2 and 15.1 in
group A, while group B, declined from 32.6 to 21.0, 14.8 and 13.6 at 1-, 3-and 6-month respectively.
The mean serum estradiol, fluctuated from the baseline of 76.6 to 55.4, 56.7, 72.5, 69.2, 114.2 and
74.5 pg/ml at 1-, 2-, 3-, 4-, 5-and 6-month respectively. Whereas the mean serum follicle-stimulating
hormone (FSH)Iluteinizing hormone (LH) was stable in the range of; 27.1112.6, 28.3/12.9 and 22.5/
11.4 miU/ml at baseline, 3-and 6-month respectively.
Conclusions :
Pueraria mirifica,
containing phytoestrogens, relatively alleviated the climac-
teric symptoms in perimenopausal women. The transient negative profiles occurred in a small number
of subjects that included anemia, and liver profiles. While there was a slight decrease in lipoproteins
and an increase in hormonal profiles,
Pueraria mirifica
demonstrates great promise in the treatment
of climacteric symptoms among peri menopausal women. However, optimal doses should be clinically
assessed, to meet appropriate individual responses.
Key word :
Pueraria miri.fica,
Vasomotor Symptoms, Perimenopausal Women, Phytoestrogen
Download:
PDF